Why LTO Validity Varies: The 3, 6 and 12 Year Rules by Enterprise Size

1. Key takeaways

Under AO No. 2024-0015 (November 2024), the validity of an LTO is tiered by enterprise size: micro and small enterprises receive 3 years on first issuance and 6 years on renewal, while medium and large enterprises receive 6 years on first issuance and 12 years on renewal. Size is determined under RA No. 9501, the Magna Carta for Micro, Small and Medium Enterprises, on the basis of asset value. An LTO that is not renewed within 120 days of expiry will be terminated by the FDA.

• Duration is earned: the first cycle is shorter because the regulator has no track record, the renewal cycle is longer because one has been established.
• Size is self-declared but verified: the asset position drives both duration and fee, and it is checked against financial documents.
• Hard deadline: 120 days after expiry, the licence is terminated rather than merely late.
• Consistent rule design: the same 120 day red line applies to registration certificates.

2. Legal basis

The duration rules and the size test come from different instruments and should be read together, because the enterprise size declared for one purpose determines the outcome for the other.

3. Expert insights

First insight: the tiering converts compliance performance into licence duration. The design logic is visible in the numbers. On first issuance the regulator does not yet know the applicant, so it grants a shorter period, three years for micro and small enterprises or six years for medium and large ones. On renewal the applicant has passed one full regulatory observation cycle, so the period doubles to six or twelve years. This is an incentive mechanism built out of time rather than penalties. For the enterprise it means that the long-run cost of holding an LTO depends on conduct and record, not only on the fee paid at renewal. A holder that accumulates inspection findings pays for them in shorter cycles and more frequent filing work.

Second insight: size is based on declared assets, and the declaration is verified. Size is assigned under RA No. 9501 by asset value. The operative point is that the declared assets are substantively verified: the FDA states that financial documents will be checked during inspection and through the life of the LTO, and that any under-declaration will be treated as a false statement and will ground regulatory action. This creates a genuine tension, because over-declaring assets to obtain a longer validity period and under-declaring them to pay a lower fee are opposite strategies, and both carry risk. GRZAN advises accurate declaration and planning around the resulting cycle length, rather than engineering the declaration.

Third insight: the current LTO fees are also tiered by assets, but not on identical boundaries. Under AO No. 50 s. 2001, which applies during the suspension of AO 2024-0016, the LTO fee for a medical device manufacturer is charged in three asset bands: PHP 5,000 where assets are PHP 20 million or below, PHP 7,000 where assets exceed PHP 20 million but are below PHP 50 million, and PHP 10,000 where assets are PHP 50 million or above, each with 1 percent LRF added. The same size logic underlies the validity tiers, but the two systems are not exactly equivalent, so a company sitting near a band boundary should map its position against both rather than assuming one follows from the other.

Fourth insight: 120 days is the cliff for an LTO, matching the logic applied to registration certificates. Philippine deadline design shows clear internal consistency. A registration certificate that is more than 120 days overdue will not be accepted for renewal and must be applied for afresh; an LTO that is not renewed within 120 days is terminated. The two periods are built on the same principle, which allows a company to run a single expiry management rule across its portfolio: every FDA authorisation has a 120 day red line. The practical benefit is administrative simplicity. The practical danger is that a single missed reminder can convert a routine renewal into a new application with a full review cycle attached.

4. Practical recommendations

• Register three data points on the day the licence is issued. The LTO number, the expiry date, and the enterprise size tier on which the duration was based.
• Start renewal preparation six months ahead. In particular, assemble the source list and contracts early, since these have been mandatory since 2026.
• Declare financial information accurately. Avoid any under-declaration that could be characterised as a false statement.
• Notify material changes in size. A significant change in assets shifts both the tier and the fee, and voluntary updating is preferable to being corrected at inspection.
• Run LTO and certificate expiries on one register. Apply the same 120 day rule to both so that the compliance calendar does not depend on two different procedures.

5. Verification checklist

• □ Enterprise size tier confirmed by asset value under RA No. 9501
• □ First issuance duration confirmed as 3 years for micro or small, or 6 years for medium or large
• □ Renewal duration confirmed as 6 years for micro or small, or 12 years for medium or large
• □ Renewal filing scheduled within 90 days before expiry, consistent with the treatment of registration certificates
• □ 120 day lapse line entered in the compliance calendar
• □ Current fee schedule confirmed as the AO No. 50 s. 2001 tiers
• □ Financial documents authentic, whether audited statements or capital proof

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com